MuMac Ltd.

What MuMac Ltd. does

MuMac Ltd. is a UK-based medical device spin-out from the University of Manchester, founded by David Carden, Professor Ian Murray, and Dr. Jeremiah Kelly. The company commercializes patented dark adaptation measurement technology developed by its founders, and its core product, RapiDA, is a digital dark adaptometer designed for the early detection of Age-Related Macular Degeneration (AMD). RapiDA uses a dual-stimulus method (an arc-shaped green stimulus on a red background) to measure rod photoreceptor recovery in low lighting conditions, completing screening in approximately five minutes with clinical-trial-reported sensitivity of 19/20 and specificity of 18/20. The device is MHRA-approved as a medical device for research, supported by National Institute of Health Research (NIHR)-funded clinical trials, and is protected by US Patent 9,526,413.

The company pursues a direct-sales model targeting eye clinics, ophthalmology practices, and healthcare systems (principally the NHS in England), positioning RapiDA as a functional biomarker screening tool for busy clinical settings that can be operated by non-specialist staff. Pricing is not publicly disclosed and the company has no named reference customers in the available data. Revenue is generated through hardware sales of the RapiDA device. The company has signaled further product development in its pipeline and has appointed senior medtech commercial experience via Non-Executive Director Dr. Bill Pigg (formerly of Smith & Nephew, Johnson & Johnson, Systagenix, and Acelity). The firm is privately held by its founders with no disclosed external venture or institutional investors.

Within its addressable market, MuMac operates against a backdrop of significant demand: AMD affects roughly 30% of those over 65 in developed countries, with 3.65 million sufferers in the UK and 196 million cases globally, against a $7.8 billion AMD drug market growing at 7.8% annually. Mumac's commercialization remains early-stage, with MHRA clearance presently scoped to research, no disclosed revenue, and 1-10 employees reported.

Name

MuMac Ltd.

Legal name

MuMac Ltd.

Website

https://mumacltd.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

MuMac Ltd. is a University of Manchester spin-out that develops and sells RapiDA, a digital dark adaptometer medical device for early screening of Age-Related Macular Degeneration, targeting eye clinics and healthcare systems such as the NHS.

Ownership category

akta.pro rank

Product category

Ophthalmic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Optical Instruments & Lenses (3827)

akta.pro primary industry

Visual Field & Functional Vision Testing (Perimetry, ERG/VEP, Contrast Sensitivity) (HLAHAJAC)

Keywords

• Ophthalmic medical devices
• Dark adaptometry screening
• AMD diagnostic instruments
• Clinical ophthalmology equipment
• Retinal health screening

Headquarters

HQ city

Manchester

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. RapiDA Device Sales: Sale of RapiDA digital dark adaptometer medical devices to eye clinics and healthcare providers for AMD screening.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

MuMac Ltd. develops and sells RapiDA, a digital dark adaptometer medical device that detects Age-Related Macular Degeneration (AMD) at the earliest possible stage by measuring how quickly the eye recovers sensitivity in dim lighting conditions. The five-minute screening test uses patented dark adaptation measurement technology with a dual stimulus method and real-time data analysis. The device is MHRA-approved for research, designed for use by non-specialist operators, and targets eye clinics, ophthalmology practices, and healthcare systems.

Product overview

MuMac Ltd. is a University of Manchester spin-out company specializing in innovative ophthalmic instruments. The company's primary product is RapiDA, a digital dark adaptometer that detects Age-Related Macular Degeneration (AMD) at early stages through patented dark adaptation measurement technology. The core product portfolio includes RapiDA as the main commercial offering, alongside prior ophthalmic instruments developed by the founders such as the Macular Pigment Screener (MPS) and Ocular Stress Monitor. The company is developing other innovative products in its pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

• RapiDA

Quantifiable outcome

• 19 of 20 AMD patients correctly identified (sensitivity)
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Optos (Nikon): Optos manufactures ultra-widefield retinal imaging devices used for AMD and retinal disease screening in optometry and ophthalmology. It targets the same AMD detection workflow as RapiDA via a different (structural imaging) modality.
• Konan Medical: Konan Medical manufactures ophthalmic diagnostic devices including functional vision testing and electrophysiology instruments used in AMD and retinal disease workups. It competes with RapiDA for clinical ophthalmology slots focused on functional, not just structural, retinal assessment.
• Reichert Technologies: Reichert manufactures ophthalmic instruments including visual field analyzers and other functional vision testing devices used in eye clinics. It overlaps with RapiDA's functional vision testing positioning in the same ophthalmology channel.
• iCare (CenterVue): iCare, through its CenterVue acquisition, produces retinal imaging and perimetry devices used in ophthalmic diagnostics including AMD assessment. It serves the same ophthalmology customer base as MuMac with a portfolio of structural and functional vision devices.
• MacuLogix (AdaptDx): MacuLogix developed the AdaptDx, a digital dark adaptometer for early AMD detection — the closest direct competitor to MuMac's RapiDA. Both devices use rod-recovery dark adaptation as a functional biomarker for early AMD, competing head-to-head for the same ophthalmology and optometry customers.

Broad incumbents

• Carl Zeiss Meditec: Carl Zeiss Meditec provides a broad ophthalmic diagnostic portfolio including OCT and retinal imaging used in AMD assessment. As a diversified incumbent with an installed base of imaging devices, it is the principal structural-imaging alternative to RapiDA in clinical practice.
• Heidelberg Engineering: Heidelberg Engineering is a leading manufacturer of OCT and confocal ophthalmic imaging systems widely used in AMD diagnosis. As a broad incumbent, it offers overlapping diagnostic capability but does not specialize in functional dark adaptation testing like RapiDA.
• Nidek: Nidek produces ophthalmic diagnostic equipment including OCT and retinal imaging systems used in AMD and retinal disease clinics. It serves the same ophthalmology and optometry buyers as MuMac with a broader, primarily structural-imaging portfolio.
• Topcon Healthcare: Topcon manufactures OCT, fundus cameras, and other ophthalmic diagnostic devices used by eye clinics globally. It overlaps with RapiDA's clinical customer base and represents the structural-diagnostic incumbent that RapiDA must position alongside or against.

Emerging players

• Notal Vision: Notal Vision developed ForeseeHome, a home-based preferential hyperacuity perimetry test for AMD monitoring. It is an emerging player in the same AMD-detection space but focused on home monitoring between clinic visits rather than in-clinic screening like RapiDA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/mumac-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MuMac Ltd.